

July 27, 2017

To Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), <b>MUMBAI -400 051</b>  <b>Company Code No. AUROPHARMA</b>	To The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> floor, Dalal Street, <b>MUMBAI -400 001</b>  <b>Company Code No. 524804</b>
--	--

Dear Sir,

**Sub: Board Meeting to consider the Un-audited Financial Results of the Company for the first quarter ended 30<sup>th</sup> June, 2017.**

We hereby inform pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that a Meeting of the Board of Directors of the Company will be held on **Wednesday 9<sup>th</sup> August, 2017** to consider and approve, inter alia, the Un-audited Financial Results of the Company for the first quarter ended 30<sup>th</sup> June, 2017.

Further to our letter dated 24<sup>th</sup> July, 2017 informing the closure of Trading Window of the Company from 27<sup>th</sup> July, 2017 until 48 hours from the date of declaration of the Un-audited Financial Results of the Company for the first quarter ended 30<sup>th</sup> June, 2017, we would like to inform you that the Trading Window will be closed up to 11<sup>th</sup> August, 2017 and shall be re-opened on 12<sup>th</sup> August, 2017.

Please take the information on record.

Thanking you,

Yours faithfully,  
**For AUROBINDO PHARMA LIMITED**

*B. Reddy*

**B. Adi Reddy**  
Company Secretary

